NervGen Kicks Off Pivotal Phase 3 Test of NVG-291 in Chronic Spinal Cord Injury NervGen Pharma Corp. (NGEN:NASDAQ) has initiated its pivotal Phase 3 trial of NVG-291 for chronic spinal cord injury, dosing the first patient. Topline data is anticipated in the first half of 2028. However, one newsletter writer cautions that investors may face a lengthy wait for results, emphasizing the importance of patience in biotech investments. The outcome could significantly impact treatment options for spinal cord injuries. #NervGen #ChronicSpinalCordInjury #BiotechInvesting streetwisereports.com/articl…

Solving a 10,000-Pound Problem: This Company Aims to Reinvent the Brain Scan Grey Matters Health Inc. is on the verge of a breakthrough in medical imaging with the upcoming launch of its first dedicated brain PET imaging clinic. As new Alzheimer's treatments emerge, the demand for earlier and more specialized imaging has never been greater. This innovative approach aims to enhance diagnostic accuracy and improve patient outcomes by providing detailed insights into brain health. By focusing on advanced imaging techniques, Grey Matters Health is positioning itself at the forefront of a critical shift in how neurological conditions are diagnosed and treated. Could this be the key to revolutionizing brain health diagnostics? Stay tuned for updates on Grey Matters Health's journey and its impact on the future of Alzheimer's care! #GreyMattersHealth #BrainImaging #Alzheimers #MedicalInnovation #Healthcare streetwisereports.com/articl…

Sernova and Seraxis Bet on BetaNova to Take Diabetes Cell Therapy Into the Clinic. Sernova Biotherapeutics Inc. (SVA:TSX | SEOVF:OTCQB | PSH0:XETRA) and Seraxis Holdings Inc. are advancing toward a merger to create BetaNova Biotherapeutics, targeting a Type 1 diabetes cell therapy clinical trial in early 2027. #Biotech #PharmaNews #DiabetesResearch #CellTherapy #MarketUpdates streetwisereports.com/articl… Find out why one featured analyst believes Sernova has found the right strategic partner. Disclosure & Legal Disclaimer: Sponsored content. This post is for informational purposes only and does not constitute investment advice or a solicitation to buy or sell securities. Early-stage biotechnology, clinical development, and stock investments carry high financial risk. Read our full disclosures and legal disclaimer via the link in our bio.

Nektar's Phase 2b Data Shows Durable Eczema, Alopecia Response. Nektar Therapeutics (NKTR:NASDAQ) reports durable Phase 2b responses for rezpegaldesleukin in eczema and alopecia areata, as the Treg-targeted drug advances toward Phase 3. streetwisereports.com/articl…

Aldeyra Plans FDRR to Appeal FDA. Aldeyra Therapeutics Inc. (ALDX:NASDAQ) announces intent to submit Formal Dispute Resolution Request appealing March 2026 CRL for reproxalap in dry eye disease. Here is a plain-English guide to the FDA appeal process for investors. streetwisereports.com/articl…

Rocket Pharmaceuticals Advances Danon Disease Gene Therapy Trial With FDA Alignment. Rocket Pharmaceuticals Inc. (RCKT:NASDAQ) receives FDA alignment to continue its Phase 2 RP-A501 trial for Danon disease, with nine additional patients expected to be treated by mid-2027. streetwisereports.com/articl…

Fennec Pharmaceuticals Reports PEDMARK Data Showing Reduced Hearing Loss in Japanese Study. Fennec Pharmaceuticals Inc. (FENC:NASDAQ;FRX:TSE) reports Phase 2 STS-J01 results for PEDMARK in Japan, with ASHA-defined hearing loss in 24% of patients versus a 56.4% benchmark. streetwisereports.com/articl…

Coya Enrolls 100 Patients in Phase 2/3 ALS Trial of COYA 302. Coya Therapeutics reaches 100-patient enrollment in its Phase 2/3 ALSTARS trial for COYA 302 in ALS, with full enrollment and topline data expected soon. Learn key catalysts for investors. streetwisereports.com/articl…

Medicus's Pfizer Deal Was Not a Fire Sale: A Strategic Bet on De-Risked ADC Drug. Mike Sheikh shares his thoughts on Medicus Pharma Ltd. (MDCX:NASDAQ) after its recent deal with Pfizer Inc. (PFE:NYSE). streetwisereports.com/articl…

Coya Therapeutics Advances COYA 302 ALS Trial With 100th Participant. Coya Therapeutics Inc. (COYA:NASDAQ) enrolls its 100th participant in the Phase 2/3 ALSTARS trial of COYA 302 for ALS, with topline data expected in early Q2 2027. streetwisereports.com/articl…

Rocket Pharmaceuticals Advances Danon Disease Gene Therapy Trial With FDA Alignment. Rocket Pharmaceuticals Inc. (RCKT:NASDAQ) receives FDA alignment to continue its Phase 2 RP-A501 trial for Danon disease, with nine additional patients expected to be treated by mid-2027. streetwisereports.com/articl…

Rocket Doctor AI Delivers 3625 U.S. Patient Visits in July and August. Rocket Doctor AI reports 3,625 completed U.S. patient visits in the first two months of Q3 2026. The update highlights ongoing U.S. expansion and telehealth momentum for retail investors. streetwisereports.com/articl…

US Patient Visits Reach 93% of Prior Quarter's Total in Two Months. Rocket Doctor AI Inc. (AIDR:CSE; AIRDF:OTC; 939:FRA) reported 3,625 completed U.S. patient visits in July and August, alongside 1,555 clinical hours as its U.S. operations expanded. streetwisereports.com/articl…

Massachusetts Biotech's Flagship Gene Therapy Posts Fifth Straight Quarterly Decline as Muscular Dystrophy Data Loom. The company's flagship gene therapy posted a fifth consecutive sequential decline in 2Q26, with DM1 and FSHD data updates seen as the next potential value inflection points. streetwisereports.com/articl…

Chart Buy Signals After Co. Targeting U.S. Alzheimer's Market Reports Final Major Regulatory Milestone. Technical Analyst Stewart Thomson reviews Grey Matters Health Inc. (GREY:CSE; AGNPF:OTCQB; AGW0:FRA) following its achievement of a major regulatory milestone. streetwisereports.com/articl…

BioLargo Subsidiary Secures Spartan Medical Deal for ViaCLYR Government Sales. BioLargo subsidiary Clyra enters an exclusive reseller agreement with Spartan Medical for ViaCLYR wound care solution targeting U.S. government facilities and ECAT listing amid expanding wound care demand. streetwisereports.com/articl…

Cleantech Firm Expands Breakthrough Wound Solution to Veterans. BioLargo Inc. (BLGO:OTCQX) is bringing its FDA-cleared ViaCLYR wound solution to U.S. government and VA-contracted healthcare facilities through a new deal with Spartan Medical. streetwisereports.com/articl…

Sernova-Seraxis Merger to Create BetaNova with US$10M for T1D Islet Trial. Sernova and Seraxis have entered into a definitive agreement to merge and create BetaNova Biotherapeutics, with US$10 million in financing to advance stem cell-derived islet therapy for type 1 diabetes, targeting Phase 1/2 data by mid-2027. streetwisereports.com/articl…

Biotechs Combine to Target Type 1 Diabetes Treatment. Sernova Biotherapeutics Inc. (SVA:TSX; SEOVF:OTCQB; PSH0:XETRA) has agreed to merge with privately held Seraxis to form BetaNova Biotherapeutics, a U.S.-based company advancing cell therapies for type 1 diabetes. Find out why one analyst calls the combination a good strategic move. streetwisereports.com/articl…

AI Cancer Drug Pipeline Advances as 72% of Budget Shifts to Drug Discovery. Rakovina Therapeutics Inc. (RKV:TSX.V) cut its Q2 net loss 41% year over year while advancing three AI-powered cancer drug programs and closing a CA$1.99 million non-brokered private placement after quarter-end. streetwisereports.com/articl…